Search Results - "Pieczonka, C."

2502 TAK-385, an oral GnRH antagonist: efficacy and safety results from a randomized phase 2 trial in prostate cancer patients (pts) by Shore, N, Bailen, J, Pieczonka, C, MacLean, D, Shi, H, Faessel, H, Saad, F

Get full text

2526 Immune responses and clinical data from STRIDE, a randomized, phase 2, open label study of sipuleucel-T with concurrent vs sequential enzalutamide administration in metastatic castrationresistant prostate cancer by Petrylak, D, Quinn, D, Dreicer, R, Antonarakis, E, Shore, N, Corman, J, Concepcion, R, Pieczonka, C, Chang, N, DeVries, T, Sheikh, N, Drake, C

Get full text

1387P Final analysis of the phase Ib/II study of sabizabulin in men with metastatic castration-resistant prostate cancer who progressed on an androgen receptor targeting agent by Markowski, M.C., Eisenberger, M., Pieczonka, C., Rodriguez, D., Barnette, K.G., Getzenberg, R.H., Steiner, M.S., Saltzstein, D.R., Antonarakis, E.S., Tutrone, R.F.

Get full text

Sabizabulin has both cytotoxic and cytostatic activity in Phase 1b/2 clinical of men with metastatic castration resistant prostate cancer who progressed on androgen receptor targeting agents by Markowski, M., Eisenberger, M., Pieczonka, C., Getzenberg, R.H., Rodriguez, D., Barnette, K.G., Steiner, M.S., Saltzstein, D., Antonarakis, E., Tutrone, R.

Get full text

599P A phase I dose-escalation study of LAE001/prednisone plus afuresertib in patients with metastatic castration-resistant prostate cancer (mCRPC) following standard of care (SOC) treatment by Bessudo, A., Wang, X., Strauss, J.F., Slater, D.E., Pieczonka, C., Guo, P., Liu, J., Yue, Y., Lu, C.

Get full text

Clinical study of VERU-111, an oral cytoskeletal disruptor in men with metastatic Castration Resistant Prostate Cancer (mCRPC) who failed an androgen receptor targeting agent by Getzenberg, R., Markowski, M.C., Tutrone, R., Eisenberger, M.A., Pieczonka, C., Rodriguez, D., Barnette, K.G., Steiner, M.S., Saltzstein, D.R., Antonarakis, E.S.

Get full text

1817P A phase I/II efficacy and safety study of LAE001/prednisone and afuresertib in patients with metastatic castration-resistant prostate cancer (mCRPC) following 1-3 lines of standard of care by Diamond, E., Kwak, C., Orr, D., Bamidele, A., Jeong, I.G., Bessudo, A., Dunshee, C., Henderson, S., Joung, J.Y., Lee, S., Chaves, J., Slater, D., Patnaik, A., Pieczonka, C., Lee, W., Choi, Y.D., Guo, P., Ma, K., Cao, E., Yue, Y.

Get full text

1778P Treatment (tx) of high-risk biochemically recurrent prostate cancer with enzalutamide (enza) in combination with leuprolide acetate (LA): Secondary endpoints from EMBARK by Freedland, S.J., Gleave, M.E., De Giorgi, U.F.F., Rannikko, A., Pieczonka, C., Sridharan, S., Brasso, K., Woo, H., Gomez Caamaño, A., Saranchuk, J., Nordquist, L.T., Ferreira, U., Tang, Y., Rosbrook, B., Haas, G.P., Rosales, M., Zohren, F., Shore, N.D.

Get full text

1766MO Health-related quality of life (HRQoL) in nonmetastatic hormone-sensitive prostate cancer (nmHSPC) patients (pts) with high-risk biochemical recurrence (BCR) from the EMBARK study by Freedland, S.J., Gleave, M.E., De Giorgi, U.F.F., Rannikko, A., Pieczonka, C., Tutrone, R., Venugopal, B., Woo, H., Ramirez Backhaus, M., Supiot, S., Lantz, A., Ganguli, A., Ivanova, J., Kral, P., Huang, S-P., Saad, F., Shore, N.D.

Get full text

615MO Phase Ib/II study of VERU-111, novel, oral tubulin inhibitor, in men with metastatic castration resistant prostate cancer (mCRPC) who failed an androgen blocking agent by Markowski, M., Eisenberger, M.A., Tutrone, R., Pieczonka, C., Getzenberg, R.H., Rodriguez, D., Barnette, K.G., Steiner, M.S., Saltzstein, D.R., Antonarakis, E.S.

Get full text

674 Early experience of radium-223 treatment for metastatic castrate resistant prostate cancer: A preliminary report by Mouraviev, V, Telonis, D, Zehel, D, Pieczonka, C, Albala, D, Williams, H, Alom, M, Mariados, N, Bienz, M

Get full text

Neo/adjuvant ADT to EBRT: Randomized phase 2 trial of the oral GnRH antagonist, TAK-385 (relugolix, RGX) and degarelix (DGX) in patients (pts) with prostate cancer (PC) by Dearnaley, D., Saltzstein, D.R., Sylvester, J.E., Karsh, L., Mehlhaff, B.A., Pieczonka, C., Bailen, J.L., Maclean, D.B., Sankoh, S., Faessel, H.M., Lin, H.M., Shore, N.D.

Get full text

Erectile function after anterior urethroplasty by Coursey, J W, Morey, A F, McAninch, J W, Summerton, D J, Secrest, C, White, P, Miller, K, Pieczonka, C, Hochberg, D, Armenakas, N

“…We ascertained the impact of anterior urethroplasty on male sexual function. A validated questionnaire was mailed to 200 men who underwent anterior…”
Get more information

An automated end-point microassay for adenosine-5′-triphosphate using a microplate reader by Pieczonka, Christopher M., Dehn, Paula F.

Get full text